[EN] LOW MOLECULAR WEIGHT 2,5-DISUBSTITUTED THIOPHENE DERIVATIVES AND USE THEREOF IN THERAPY<br/>[FR] DÉRIVÉS DE THIOPHÈNE 2,5-DISUBSTITUÉS DE FAIBLE POIDS MOLÉCULAIRE ET LEUR UTILISATION EN THÉRAPIE
申请人:NOVASAID AB
公开号:WO2009098282A1
公开(公告)日:2009-08-13
A compound of formula (I). The compound is useful for the treatment of disorders such as pain, fever, inflammation and cancer. A method for preparing the compound.
一种化合物的化学式(I)。该化合物可用于治疗疼痛、发热、炎症和癌症等疾病。一种制备该化合物的方法。
PYRAZOLE COMPOUNDS SUBSTITUTED WITH HETEROARYL AND PHARMACEUTICAL USE THEREOF
申请人:Japan Tobacco Inc.
公开号:US20190330193A1
公开(公告)日:2019-10-31
Pyrazole compounds substituted with heteroaryl or pharmaceutically acceptable salts thereof that have an SGLT1 inhibitory activity and are useful for a drug, pharmaceutical compositions comprising the same, and pharmaceutical use thereof are disclosed. Specifically, a compound of Formula [X]:
wherein R
1
is hydrogen or halogen, R
2
is C
1-6
alkyl or halo-C
1-6
alkyl, Ring Het is substituted pyridyl or optionally substituted pyrazinyl, pyrimidinyl, or pyridazinyl, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising it, and pharmaceutical use thereof is provided.
Compounds of formula I wherein R1, R2, R3, R4 and R5 have the means set forth in the description are selective cyclic nucleotide phosphodiesterase (PDE) inhibitors (specifically of type 4), which are effective bronchial therapeutics.
This invention is directed to a tetrahydro-indazole cannabinoid modulator compound of formula I:
and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.
Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof
申请人:Japan Tobacco Inc.
公开号:US10988462B2
公开(公告)日:2021-04-27
Pyrazole compounds substituted with heteroaryl or pharmaceutically acceptable salts thereof that have an SGLT1 inhibitory activity and are useful for a drug, pharmaceutical compositions comprising the same, and pharmaceutical use thereof are disclosed. Specifically, a compound of Formula [X]:
wherein R1 is hydrogen or halogen, R2 is C1-6 alkyl or halo-C1-6 alkyl, Ring Het is substituted pyridyl or optionally substituted pyrazinyl, pyrimidinyl, or pyridazinyl, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising it, and pharmaceutical use thereof is provided.